Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: KurtVedder who wrote (1074)	3/4/1998 12:16:00 AM
From: cardiologist to be	Read Replies (2) \| Respond to of 1359

regarding ipic. 1st, don't believe anyone when they say that phen/fen doesn't cause valvular damage. i was just at a cardiology conference and it was the consensus that nearly 1 of 8 echocardiogram's being done are in relation to pts on phen/fen or redux. the impression is that cardiac patients are sometimes forced to wait so that these echos can be done on phen/fen pts. 2nd, don't believe that redux,phen/fen litigation is going to disappear quickly. litigation of this nature will drag on for the next 5 years and will occassionally impact stock prices on bad news. 3rd. buy ipic 4th why? because bucindolol is getting good results in clinical trials and will be a competitor to carvedilol. heart failure will always be a big problem in this country and the usage of beta blockers like carvedilol and bucindolol is abysmal. also, i like another poster on this board have family who believe strongly in ceraxon and have heard from prominent neurologists that it will be a blockbuster. 5th. i think your pricing is a little too optimistic because of 1 and 2. ipic will likely be a great investment, but i doubt we will see a 4 or 5 bagger this year. double to triple is more likely once fda approves ceraxon, and that is still optimistic. just my thoughts.